Effectiveness of BA.1-and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan

被引：11

作者：

Arashiro, Takeshi ^{[1
,2
,3
,4
]}

Arima, Yuzo ^{[1
]}

Kuramochi, Jin ^{[5
,6
]}

Muraoka, Hirokazu ^{[7
]}

Sato, Akihiro ^{[8
]}

Chubachi, Kumi ^{[9
]}

Yanai, Atsushi ^{[10
]}

Arioka, Hiroko ^{[10
]}

Uehara, Yuki ^{[11
,12
]}

Ihara, Genei ^{[13
]}

Kato, Yasuyuki ^{[14
]}

Yanagisawa, Naoki ^{[15
]}

Ueda, Akihiro ^{[16
]}

Kato, Hideaki ^{[17
]}

Oka, Hideaki ^{[18
]}

Nishida, Yusuke ^{[18
]}

Nidaira, Yuki ^{[5
]}

Asami, Takahiro ^{[19
]}

Jinta, Torahiko ^{[20
]}

Nakamura, Akira ^{[21
]}

Oba, Kunihiro ^{[22
]}

Taniyama, Daisuke ^{[23
]}

Yamamoto, Kei ^{[18
]}

Tanaka, Katsushi ^{[17
]}

Ueshima, Kankuro ^{[24
]}

Fuwa, Tetsuji ^{[24
]}

Stucky, Ashley ^{[1
]}

Suzuki, Tadaki ^{[2
]}

Smith, Chris ^{[3
]}

Hibberd, Martin ^{[3
]}

Ariyoshi, Koya ^{[4
]}

Suzuki, Motoi ^{[1
]}

机构：

[1] Natl Inst Infect Dis, Ctr Surveillance Immunizat & Epidemiol Res, Tokyo, Japan

[2] Natl Inst Infect Dis, Dept Pathol, Tokyo, Japan

[3] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England

[4] Nagasaki Univ, Sch Trop Med & Global Hlth, Nagasaki, Japan

[5] Kuramochi Clin Interpk, Tochigi, Japan

[6] Tokyo Med & Dent Univ, Dept Global Hlth Promot, Tokyo, Japan

[7] Clin TAMACHI, Tokyo, Japan

[8] KARADA Internal Med Clin, Tokyo, Japan

[9] Chubachi Internal Resp Med Clin, Tokyo, Japan

[10] St Lukes Int Hosp, Dept Gen Internal Med, Tokyo, Japan

[11] St Lukes Int Hosp, Dept Clin Lab, Tokyo, Japan

[12] Fujita Hlth Univ, Sch Med, Dept Infect Dis, Aichi, Japan

[13] Machida Ekimae Naika Clin, Tokyo, Japan

[14] Int Univ Hlth, Welf Narita Hosp, Dept Infect Dis, Chiba, Japan

[15] Yanagisawa Clin, Tokyo, Japan

[16] Japanese Red Cross Med Ctr, Dept Infect Dis, Tokyo, Japan

[17] Yokohama City Univ Med, Infect Prevent & Control Dept, Yokohama, Japan

[18] Saitama Med Ctr, Dept Gen Internal Med & Infect Dis, Saitama, Japan

[19] Sano Kosei Gen Hosp, Dept Internal Med, Tochigi, Japan

[20] St Lukes Int Hosp, Dept Pulm Med, Tokyo, Japan

[21] Asahi Gen Hosp, Dept Internal Med, Chiba, Japan

[22] Showa Gen Hosp, Dept Pediat, Tokyo, Japan

[23] Showa Gen Hosp, Dept Infect Dis, Tokyo, Japan

[24] NATURALI Co Ltd, Tokyo, Japan

来源：

OPEN FORUM INFECTIOUS DISEASES | 2023年 / 10卷 / 06期

关键词：

COVID-19; SARS-CoV-2; variants; test-negative design; vaccine effectiveness;

D O I：

10.1093/ofid/ofad240

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined). In this multi-center study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent vaccines against symptomatic infection during the BA.5-dominant period was high compared to no vaccination (65%/76%) and moderate compared to monovalent vaccines >6 months before (46% combined).

引用

页数：6

共 50 条

[41] Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa
Houriiyah Tegally
Monika Moir
Josie Everatt
Marta Giovanetti
Cathrine Scheepers
Eduan Wilkinson
Kathleen Subramoney
Zinhle Makatini
Sikhulile Moyo
Daniel G. Amoako
Cheryl Baxter
Christian L. Althaus
Ugochukwu J. Anyaneji
Dikeledi Kekana
Raquel Viana
Jennifer Giandhari
Richard J. Lessells
Tongai Maponga
Dorcas Maruapula
Wonderful Choga
Mogomotsi Matshaba
Mpaphi B. Mbulawa
Nokukhanya Msomi
Yeshnee Naidoo
Sureshnee Pillay
Tomasz Janusz Sanko
James E. San
Lesley Scott
Lavanya Singh
Nonkululeko A. Magini
Pamela Smith-Lawrence
Wendy Stevens
Graeme Dor
Derek Tshiabuila
Nicole Wolter
Wolfgang Preiser
Florette K. Treurnicht
Marietjie Venter
Georginah Chiloane
Caitlyn McIntyre
Aine O’Toole
Christopher Ruis
Thomas P. Peacock
Cornelius Roemer
Sergei L. Kosakovsky Pond
Carolyn Williamson
Oliver G. Pybus
Jinal N. Bhiman
Allison Glass
Darren P. Martin
Nature Medicine, 2022, 28 : 1785 - 1790
[42] Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France
Tamandjou, Cynthia
Auvigne, Vincent
Schaeffer, Justine
Vaux, Sophie
du Chatelet, Isabelle Parent
VACCINE, 2023, 41 (17) : 2754 - 2760
[43] Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study
Tan, Celine Y.
Chiew, Calvin J.
Pang, Deanette
Lee, Vernon J.
Ong, Benjamin
Lye, David Chien
Tan, Kelvin Bryan
LANCET INFECTIOUS DISEASES, 2023, 23 (07): : 799 - 805
[44] Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
Mingxi Li
Yifei Ren
Zhen Qin Aw
Bo Chen
Ziqing Yang
Yuqing Lei
Lin Cheng
Qingtai Liang
Junxian Hong
Yiling Yang
Jing Chen
Yi Hao Wong
Jing Wei
Sisi Shan
Senyan Zhang
Jiwan Ge
Ruoke Wang
Jay Zengjun Dong
Yuxing Chen
Xuanling Shi
Qi Zhang
Zheng Zhang
Justin Jang Hann Chu
Xinquan Wang
Linqi Zhang
Nature Communications, 13
[45] Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
Li, Mingxi
Ren, Yifei
Aw, Zhen Qin
Chen, Bo
Yang, Ziqing
Lei, Yuqing
Cheng, Lin
Liang, Qingtai
Hong, Junxian
Yang, Yiling
Chen, Jing
Wong, Yi Hao
Wei, Jing
Shan, Sisi
Zhang, Senyan
Ge, Jiwan
Wang, Ruoke
Dong, Jay Zengjun
Chen, Yuxing
Shi, Xuanling
Zhang, Qi
Zhang, Zheng
Chu, Justin Jang Hann
Wang, Xinquan
Zhang, Linqi
NATURE COMMUNICATIONS, 2022, 13 (01)
[46] Analytical Sensitivity of Lateral Flow Devices against SARS-CoV-2 Omicron Subvariants BA.4, BA.5, and BA.2.75
Mackenzie, Charlene
Batty, Mitchell
Papadakis, Georgina
Stevens, Laura
Yoga, Yano
Taiaroa, George
Stefanatos, Helen
Savic, Ivana
Tran, Thomas
Deerain, Joshua
Prestedge, Jacqueline
Druce, Julian
Caly, Leon
Williamson, Deborah A.
JOURNAL OF CLINICAL MICROBIOLOGY, 2022, 60 (11)
[47] Real-world effectiveness of nirmatrelvir-ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants
Wong, Carlos K. H.
Lau, Kristy T. K.
Leung, Gabriel M.
LANCET INFECTIOUS DISEASES, 2023, 23 (06): : 639 - 640
[48] Heterologous booster vaccines reduce severity and mortality in COVID-19 during BA.2 and BA.4/BA.5 omicron predominance in Thailand
Intawong, Kannikar
Chariyalertsak, Suwat
Chalom, Kittipan
Wonghirundecha, Thanachol
Kowatcharakul, Woravut
Thongprachum, Aksara
Chotirosniramit, Narain
Noppakun, Kajohnsak
Khwanngern, Krit
Teacharak, Worachet
Piamanant, Prapon
Khammawan, Pimpinan
Iamsirithaworng, Sopon
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2023, 56 (06) : 1178 - 1186
[49] Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody
Kumar, Sanjeev
Patel, Anamika
Lai, Lilin
Chakravarthy, Chennareddy
Valanparambil, Rajesh
Reddy, Elluri Seetharami
Gottimukkala, Kamalvishnu
Davis-Gardner, Meredith E.
Edara, Venkata Viswanadh
Linderman, Susanne
Nayak, Kaustuv
Dixit, Kritika
Sharma, Pragati
Bajpai, Prashant
Singh, Vanshika
Frank, Filipp
Cheedarla, Narayanaiah
Verkerke, Hans P.
Neish, Andrew S.
Roback, John D.
Mantus, Grace
Goel, Pawan Kumar
Rahi, Manju
Davis, Carl W.
Wrammert, Jens
Godbole, Sucheta
Henry, Amy R.
Douek, Daniel C.
Suthar, Mehul S.
Ahmed, Rafi
Ortlund, Eric
Sharma, Amit
Murali-Krishna, Kaja
Chandele, Anmol
SCIENCE ADVANCES, 2022, 8 (40):
[50] Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants
Jian, Fanchong
Yu, Yuanling
Song, Weiliang
Yisimayi, Ayijiang
Yu, Lingling
Gao, Yuxue
Zhang, Na
Wang, Yao
Shao, Fei
Hao, Xiaohua
Xu, Yanli
Jin, Ronghua
Wang, Youchun
Xie, Xiaoliang Sunney
Cao, Yunlong
LANCET INFECTIOUS DISEASES, 2022, 22 (11): : 1535 - 1537

← 1 2 3 4 5 →